Autolus is a biopharmaceutical company focusing on the development of precisely targeted, controlled and highly active T effector cell therapies that are designed to offer cancer patients substantial benefits over existing standard of care.
Autolus is founded on advanced cell programming technology pioneered by Dr Martin Pule and was spun-out from University College London in 2014. Chimeric Antigen Receptor (CAR) T cell therapies have been shown to be effective in some haematological malignancies and may have wide applications as a cancer treatment, with the potential for cure in some patients.
A leader in T-cell programming and manufacturing technology, Autolus works in partnership with physicians and other healthcare providers to extract immune cells from patients, equip them with a receptor that targets the cancer cell and infuse them back into the patient in order to develop therapies which they believe will offer cancer patients substantial benefits over the existing standard of care.
Autolus is founded on advanced cell programming technology pioneered by Dr Martin Pule and was spun-out from University College London in 2014. Chimeric Antigen Receptor (CAR) T cell therapies have been shown to be effective in some haematological malignancies and may have wide applications as a cancer treatment, with the potential for cure in some patients.
A leader in T-cell programming and manufacturing technology, Autolus works in partnership with physicians and other healthcare providers to extract immune cells from patients, equip them with a receptor that targets the cancer cell and infuse them back into the patient in order to develop therapies which they believe will offer cancer patients substantial benefits over the existing standard of care.
Location: United Kingdom
Employees: 201-500
Total raised: $136.92M
Founded date: 2014
Investors 3
| Date | Name | Website |
| 21.11.2024 | Syncona Pa... | synconaltd... |
| - | Arix Biosc... | arixbiosci... |
| - | GV | gv.com |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 26.09.2017 | Series C | $80M | - |
| 04.03.2016 | Series B | $56.92M | - |
Mentions in press and media 24
| Date | Title | Description |
| 06.03.2026 | University spinouts boom as startups pull in billions | Academics are increasingly going on to start their own start-ups, with a surge in spinouts, patents and investment pointing to the growing commercial impact of Britain’s research base. New figures seen by City AM show the number of UCL acad... |
| 25.01.2026 | London's King's Cross: A Global Powerhouse Emerges | London's King's Cross has transformed into a global innovation and retail powerhouse. Once a neglected area, it now thrives as a leading tech and life sciences hub, attracting major investment and creating high-value jobs. Retail sales show... |
| 20.01.2026 | Kings Cross spinout district could create 20,000 new jobs | The innovation district around Kings Cross and Euston has the potential to grow into the UK’s version of Kendall Square, writes Professor Geraint Rees A smiling Oscar Murphy, 28, was all over the news this week. Oscar had become the first p... |
| 25.04.2025 | Autolus Therapeutics Announces License of AUCATZYL® (obecabtagene autoleucel) Issued by UK MHRA for Adult Patients (≥ 18 years) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemi... | UK Medicines and Healthcare products Regulatory Agency (MHRA) authorisation based on FELIX clinical trial of obecabtagene autoleucel in adult patients with r/r B-ALL1 AUCATZYL® licensed from MHRA under ‘conditional marketing authorisation’,... |
| 19.02.2025 | Navigating the New Standards in Aseptic Processing and ATMP Production | In the world of pharmaceuticals, standards are the compass guiding the industry through turbulent waters. Recently, two significant documents emerged from the Parenteral Drug Association (PDA), each a beacon for professionals navigating the... |
| 18.02.2025 | PDA Releases Points to Consider Number 11 for Plasmids and Vectors in ATMP Production | PDA This points to consider clarifies plasmid and viral vector categorization and control, quality by design concepts, control strategies, filtration, comparability, platform technologies and potency assays. BETHESDA, Md., Feb. 18, 2025 /PR... |
| 12.03.2024 | Autolus Therapeutics receives Medicines and Healthcare products Regulatory Agency (MHRA) certification for Nucleus commercial manufacturing site | - |
| 08.03.2024 | CAR T-Cell Therapy Market Set for Healthy Growth after COVID19 Pandemic Top Players Industry Trends and Forecast 2032 | CHICAGO, UNITED STATES, March 8, 2024 /EINPresswire.com/ -- Astute Analytica, a leading provider of market research and analysis, released its highly anticipated Market Analysis Report on the Global 𝐂𝐀𝐑 𝐓-𝐂𝐞𝐥𝐥 𝐓𝐡𝐞𝐫𝐚𝐩𝐲 𝐌𝐚𝐫𝐤𝐞𝐭. This comprehen... |
| 09.11.2021 | PE Daily: Collibra Hits $5.25 Billion Valuation | Carlyle Vet Quarles to Leave the Fed | Blackstone Backs Autolus Therapeutics | Good day and welcome back. Isaac Taylor brings us the latest news on the soaring valuation of data-technology company Collibra NV, while Nick Timiraos and Andrew Ackerman report that Randal Quarles is leaving the Federal Reserve board of go... |
| 08.11.2021 | Who would take venture dollars from Facebook right now? | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox. If you’re a startup founder, there’s a laundry list of reasons why you don’t want social media co... |
Show more